Laboratorios Farmaceuticos Rovi
Laboratorios Farmacéuticos Rovi, commonly known as Rovi, is a prominent Spanish pharmaceutical company headquartered in Madrid, Spain. Founded in 1946, Rovi has established itself as a key player in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of innovative medicines, particularly in the fields of oncology, central nervous system disorders, and anti-infectives. With a strong presence in Europe and expanding operations in international markets, Rovi is recognised for its commitment to quality and innovation. The company’s core products include injectable medications and biosimilars, which are distinguished by their high standards of efficacy and safety. Rovi's notable achievements include significant partnerships and a robust pipeline of products, positioning it as a leader in the pharmaceutical sector.
DitchCarbon Score
How does Laboratorios Farmaceuticos Rovi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laboratorios Farmaceuticos Rovi's score of 15 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Laboratorios Farmaceuticos Rovi's reported carbon emissions
In 2023, Laboratorios Farmaceuticos Rovi reported total carbon emissions of approximately 11,059,000 kg CO2e, comprising 7,859,000 kg CO2e from Scope 1, 27,000 kg CO2e from Scope 2, and 11,059,000 kg CO2e from Scope 3 emissions. This marked a slight increase in total emissions compared to previous years, with 2022 emissions recorded at about 10,352,000 kg CO2e. In 2022, Rovi's emissions included 6,693,000 kg CO2e from Scope 1, 616,000 kg CO2e from Scope 2, and 10,352,000 kg CO2e from Scope 3. The company has not disclosed specific reduction targets or initiatives, indicating a lack of formal commitments to reduce emissions as per the latest data. Overall, Rovi's emissions have fluctuated over the years, with significant contributions from both Scope 1 and Scope 3 emissions. The absence of defined reduction targets suggests that while Rovi is aware of its carbon footprint, it may not yet have established a comprehensive strategy for emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 1,135,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 3,073,000 | 0,000,000 | 000,000 | 0,000 | 000,000 | 00,000 |
| Scope 3 | 4,936,000 | - | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Laboratorios Farmaceuticos Rovi is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
